Premium
Vitiligo in a patient receiving infliximab for chronic plaque psoriasis
Author(s) -
Lu Xiya,
Gao Yunlu,
Ding Yangfeng
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12917
Subject(s) - medicine , infliximab , vitiligo , psoriasis , plaque psoriasis , dermatology , tumor necrosis factor alpha , tumor necrosis factor α
Infliximab is a tumor necrosis factor‐alpha (TNF‐a) inhibitor widely used in the treatment of moderate to severe chronic plaque psoriasis. Here, we report a case of vitiligo following infliximab administration in a patient with chronic plaque psoriasis. The case serves as a reminder of vitiligo induced by TNF‐a‐antagonist therapy.